Mikhail Blagosklonny is a distinguished research scientist with a strong focus on oncology. He serves as the senior editor of Oncotarget, a weekly journal that publishes peer-reviewed papers on topics such as oncology, neuroscience, pathology, pharmacology and many more medical fields.
He recently talked about the healing properties of Rapamycin, one of the most potent cancer drugs on the market. The drug is traditionally used to enable transplanted organs to achieve acceptance in the host body. It treats a rare lung condition and is also used as an anti-aging agent. Mikhail Blagosklonny previously served as a professor at Roswell Park Cancer Institute in New York. He has conducted extensive research in oncology and particularly the subject of aging.
He gives several reasons on why he advocates the use of Rapamycin. The drug has a comprehensive range of applications as well as advantages over classic versions. The immunosuppressive drug ensures organ transplants go smoothly.
Similarly, it is less toxic to the kidney than any other drug on the market. Rapamycin is an excellent option to treat major renal failure through a kidney transplant. In like manner, it is also the top prescription option for the treatment of rare lung disease. Other uses include the coating of coronary stents to suppress restenosis. Rapamycin boosts the immune system and stimulates its response to tumors.
This makes it a popular choice for cancer therapy. Additionally, it is useful in suppressing the growth of benign tumors in organs such as the brain and kidneys among others. It slows down the effects associated with aging and is prescribed in a cream format for the treatment of facial spots.
Mikhail Blagosklonny has been at the forefront of groundbreaking research into innovative treatment procedures that impact the quality of life. He graduated with a Ph.D. in experimental medicine from the First Pavlov State University. He then worked as an associate professor at New York Medical College. He has also served as a high-ranking researcher at Ordway Institute.
The scientist has a strong focus on cancer and anti-aging research. He is also a sought-after mentor and professor providing great inspiration and guidance to peers and students alike. He is excited to be at the forefront of discovering an effective, non-invasive and affordable cure for cancer. His research efforts have earned him widespread recognition among his peers.
The fame and prominence have only been accelerated by his role as the editor-in-chief of the Oncotarget journal. The journal recently upped its publish cycle to twice per week. As a result, it will accommodate the large volume of papers it receives and accelerate the dissemination of the information. He is also involved in editorial activities at numerous others journals including Aging, Cell Death & Differentiation as well as Cell Cycle among others.
One of his successful treatment procedures involves targeting the cancerous cells within the body while ensuring that the process does not affect healthy cells in the same areas. He is passionate about ensuring that research in cancer therapy and aging continues across the world.